CRISPR-based Ferroptosis Target Screening Services

Creative Biolabs can realize transcriptional activation of single or multiple genes, and can also realize transcriptional activation regulation of the whole genome through the gRNA library, which is used for the study of ferroptosis gene function and the screening of target genes.

Introduction to CRISPR-Based Ferroptosis Platform

Previous studies have demonstrated that ACSL4 plays a crucial role as an enzyme in generating lipid peroxides during ferroptosis. The recent discovery of the molecular mechanism behind ACSL4 activation was achieved through CRISPR-Cas9 genome-wide library screening and kinase inhibitor library screening. The CRISPR library is a high-throughput gene screening approach based on CRISPR/Cas9 technology, which utilizes functional screening, enrichment, and deep sequencing analysis to identify genes associated with specific phenotypes or to screen for new drug targets.

Fig.1 Schematic Description of a CRISPR-Cas9 Knockout Library of CARM1 as a Key Inhibitor of Ferroptosis.¹

In the realm of gene editing research, Creative Biolabs possesses extensive expertise in cellular gene editing and ferroptosis studies. We offer over 20 CRISPR libraries and comprehensive services including high-throughput sgRNA library construction, virus packaging, cell transfection, drug screening, NGS sequencing, and data analysis. For example, our recent studies have successfully validated the potential role and molecular mechanism of PKCβII in regulating ACSL4 activation to control cell fate during ferroptosis execution using CRISPR library screening. Our versatile CRISPR-based ferroptosis screening platform allows for whole-genome, gene family, or signaling pathway gene screenings due to its low noise, high knockout efficiency, and minimal off-target effects.

Nowadays, Creative Biolabs provides the full range of human/mouse genomes and CRISPR knockout gRNA library based on ferroptosis signaling pathways such as kinases, cell cycles, membrane proteins, and metabolic genes, to help you quickly screen out genes associated with phenotypes or specific functions that trigger ferroptosis, and explore potential targets, such as new genes composed of ferroptosis pathway, genes causing ferroptosis tumors.

CRISPR-Based Ferroptosis Solutions

Creative Biolabs provides three customized libraries of CRISPR-KO, CRISPRa, and CRISPRi, from high-throughput sgRNA library construction to virus packaging, cell transfection, drug screening, high-throughput sequencing, and data analysis, and a variety of delivery methods to meet different ferroptosis research needs.

Delivery Standard

1. Glycerol bacterial/plasmid carrier library customized service delivery
2. Virus library titer ≥1*10^8 TU/mL, delivery of 1mL-5mL
3. Library amplification service delivery plasmid
4. The amount of cells delivered by library transfection cells is subject to customer demand
5. One-stop CRISPR-based ferroptosis service to deliver sequencing data

Quality Control

Coverage >95%, uniformity <8.

Advantages

• In vivo/in vitro CRISPR verification: in vitro cutting efficiency exceeds 90%
• Providing high-quality CRISPR-Cas9 analysis systems for optimizing challenging gene editing conditions
• RNase-free: Strict control of RNase contamination during production
• NLS nuclear localization signal facilitates protein delivery to the nucleus, enhancing genomic DNA editing efficiency
• Broad spectrum: no genetic, cellular, or species limitations
• Multiple editing capabilities: Gene targeting at multiple ferroptosis target sites can be achieved simultaneously
• Rich functions: it can achieve knockout, insertion, inhibition, activation, and other ferroptosis target genes

Creative Biolabs focuses on ferroptosis and gene editing, and as a leading CRO company, it has launched CRISPR analysis of Cas proteins including Cas9, and Cas12a, which is mainly used for fixed-point gene editing related to ferroptosis. Please feel free to contact us for more details.

Reference

1. Cheng, Yiming, et al. "A CRISPR-Cas9 library screening identifies CARM1 as a critical inhibitor of ferroptosis in hepatocellular carcinoma cells." Molecular Therapy-Nucleic Acids 34 (2023).

For Research Use Only | Not For Clinical Use